Clinical Trials

The ultimate goal in translational medicine is to test and validate new therapeutic options in humans and to advance appropriate tools for tailored treatment. Therefore, a major aim of the DZL is to promote and enable the progress of early clinical trials, fostering these approaches.

DZL aims to facilitate innovative investigator initiated studies (IITs) in lung diseases. A particular focus of the DZL are innovative Phase IIa IITs. These might be studies in wellcharacterized subgroups of patients, to explore the option of personalized medicine (for example, in oncology, aiming to match patients with molecularly defined alterations of the tumour to specific treatments). These studies are ideally combined with predictive diagnostics approaches.

Furthermore, studies where industry is less interested or which explore new indications of already authorized or off-patent medicinal products, are in the focus of the DZL.

Innovative science can often lead in unexpected directions. In order to be able to respond to new findings in the field and translate those findings as quickly as possible to positive outcomes for patients, a portion of the DZL budget was set aside for innovative clinical trials.

Presently funded clinical trials involving BREATH:

Anti-TSLP-mab Tezepelumab in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia  
Coordinating Investigator: Prof. Dr. Antje Prasse / PD Dr. Benjamin Seeliger
Cooperating Partners: ARCN, BREATH, CPC-M, TLRC

CHANGE-MRI (CTEPH DIAGNOSIS Europe - MRI) Phase III diagnostic trial to demonstrate that functional lung MRI can replace VQ-SPECT in a diagnostic strategy for patients with suspected CTEPH
Coorditating Investigator: Prof. Dr. Jens Vogel-Claussen
Cooperating Partners: BREATH, CPC, TLRC, UGMLC

CHILD Evaluation of the efficacy and safety of hydroxychloroquine (HCQ) in pediatric interstitial lung disease (ILD)
Coordinating Investigator: Prof. Dr. M. Griese
Cooperating Partners: ARCN, BREATH, CPC, UGMLC

EMoLung Monitoring of patients with NSCLC – epigenetic analysis of liquid biopsies and RNA analysis in exhaled breath condensates (EMoLung)
Coordinating Investigators: Prof. Dr. Martin Reck, Prof. Dr. Ole Ammerpohl
Cooperating Partners: ARCN, BREATH, CPC, TLRC, UGML

Eradicate Inhaled Levofloxacin in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection
Coordinating Investigator: Prof. Dr. J. Behr
Cooperating Partners: BREATH, CPC, UGMLC

HANSE Study Holistic implementation study Assessing a Northern German interdisciplinary lung cancer screening  effort
Coordinating Investigator: Prof. Dr. J. Vogel-Claussen
Cooperating Partners: BREATH, ARCN